SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Cheryl Galt who wrote (28627)3/31/1999 4:54:00 AM
From: Henry Niman  Respond to of 32384
 
Rezulin sales are about $750 million, although WLA did have a story for Rezulin treatment of cancer. The data was for liposarcomas (which LGND and collaborators published a couple of years ago), but was extended to 500,000 cancers. Maybe WSJ thinks LGND has a large piece of the action.



To: Cheryl Galt who wrote (28627)3/31/1999 7:17:00 AM
From: Hippieslayer  Read Replies (1) | Respond to of 32384
 
1.26 billion could be the total dollar loss that shareholders incurred from the drop of the stock......... :P

hmmmm...story breaking hard!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News